Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms

References

• Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol. 2019;35(5):468–477.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr-Relat Cancer. 2008;15(2):409–427.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB et al. AJCC cancer staging manual [M]. 8th ed. New York (NY): Springer; 2016.
   Google Scholar
• Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–762.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, WHO Classification of Tumours Editorial Board, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188.
   PubMed Web of Science ®Google Scholar
• Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19(12):1029–1050.
   PubMed Web of Science ®Google Scholar
• Luo G, Javed A, Strosberg JR, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol. 2017;35(3):274–280.
   PubMed Web of Science ®Google Scholar
• Ye L, Ye H, Zhou Q, et al. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: new proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. Int J Surg (London, England). 2016;29:108–117.
   PubMed Web of Science ®Google Scholar
• Pan M, Yang Y, Teng T, et al. Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study. BMC Gastroenterol. 2021;21(1):101.
   PubMed Web of Science ®Google Scholar
• Park SY. Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang L, Ci B, et al. Development and validation of a nomogram prognostic model for SCLC patients. J Thorac Oncol: off Publ Int Assoc Stud Lung Cancer. 2018;13(9):1338–1348.
   Google Scholar
• Wang Y, Du L, Yang X, et al. A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer. Aging. 2020;12(3):2857–2879.
   PubMedGoogle Scholar
• Su J, Miao LF, Ye XH, et al. Development of prognostic signature and nomogram for patients with breast cancer. Medicine. 2019;98(11):e14617.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI). Surveillance E, and End Results Program. SEER Fact Sheets: SEER Program Overview. https://seer.cancer.gov/about/overview.html. Accessed 17 Mar, 2020.
   Google Scholar
• Zhang XF, Wu Z, Cloyd J, et al. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: results from the US Neuroendocrine Tumor Study Group. Surgery. 2019;165(3):548–556.
   PubMed Web of Science ®Google Scholar
• Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–589.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Y, Zhuang H, et al. Establishment and validation of an AJCC stage- and histologic grade-based nomogram for pancreatic neuroendocrine tumors after surgical resection. CMAR. 2019;11:7345–7352.
   Web of Science ®Google Scholar
• Fang C, Wang W, Feng X, et al. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer. 2017;117(10):1544–1550.
   PubMed Web of Science ®Google Scholar
• Xie S, Li L, Wang X, et al. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Medicine (Baltimore). 2021;100(2):e24223.
   PubMed Web of Science ®Google Scholar
• Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018;472(3):341–349.
   PubMed Web of Science ®Google Scholar
• Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(10):1134–1150.
   PubMed Web of Science ®Google Scholar
• Milione M, Maisonneuve P, Spada F, et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85–93.
   PubMed Web of Science ®Google Scholar
• Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications. Cancer Treat Rev. 2016;50:61–67.
   PubMed Web of Science ®Google Scholar
• Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 classification: real-world data from the Spanish tumor registry (R-GETNE). Oncologist. 2018;23(4):422–432.
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, et al. Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study. J Clin Oncol. 2019;37(28):2571–2580.
   PubMed Web of Science ®Google Scholar
• Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA: Cancer J Clinicians. 2018;68(6):471–487.
   PubMed Web of Science ®Google Scholar
• Deng BY, Liu F, Yin SN, et al. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: a comprehensive analysis by the World Health Organization 2010 grading classification. Clin Res Hepatol Gastroenterol. 2018;42(3):261–268.
   PubMed Web of Science ®Google Scholar
• Gorelik M, Ahmad M, Grossman D, et al. Nonfunctioning incidental pancreatic neuroendocrine tumors: who, when, and how to treat? Surg Clin North Am. 2018;98(1):157–167.
   PubMed Web of Science ®Google Scholar
• Marchegiani G, Landoni L, Andrianello S, et al. Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? Neuroendocrinology. 2019;108(3):161–171.
   PubMed Web of Science ®Google Scholar
• Paiella S, De Pastena M, Faustini F, et al. Central pancreatectomy for benign or low-grade malignant pancreatic lesions – a single-center retrospective analysis of 116 cases. Eur J Surg Oncol. 2019;45(5):788–792.
   PubMed Web of Science ®Google Scholar